Preparation and in vitro evaluation of BBG-250 loaded liposomal formulation for anticancer potential
Open Access
- 12 February 2024
- journal article
- research article
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 10 (1) , 1-16
Abstract
Background: Liposome-mediated drug delivery systems have emerged as a promising avenue for enhancing cancer treatment strategies. This study aims to develop and assess liposomal carriers loaded with Brilliant Blue G-250 (BBG-250), a potent P2X7 receptor antagonist that shows potential as an anti-tumor agent. Specifically, two types of liposomal formulations were designed: conventional liposomes composed of hydrogenated soya phosphatidylcholine (HSPC) and cholesterol, and pH-sensitive liposomes consisting of dioleoylphosphatidylethanolamine (DOPE), distearoylphosphatidylethanolamine-methoxy polyethylene glycol (DSPE-mPEG), dipalmitoylphosphatidylcholine (DPPC), and cholesterol. The investigation focuses on understanding the morphological characteristics, size, stability, drug incorporation efficiency, drug release profiles, blood compatibility, and cytotoxicity of these liposomal formulations. Results: Advanced photon correlation spectroscopy using the Nano Plus-3 instrument was employed to evaluate the liposomes. The optimized conventional liposomes (HSPC-cholesterol ratio 7:3) exhibited a size of 125 ± 0.3 nm with a polydispersity index (PDI) of 0.21, indicating uniformity. The pH-sensitive liposomes (DOPE:DPPC:DSPE-PEG2000: Cholesterol 4:3:3:0.3) demonstrated a size of 118 ± 1.2 nm with a PDI of 0.230. Zeta potential measurements confirmed the stability of both formulations under physiological conditions, with values of − 16.93 mV for conventional liposomes and − 25.21 mV for pH-sensitive liposomes. Higher drug-to-lipid ratios were found to enhance drug incorporation efficiency. pH-sensitive liposomes exhibited superior drug release characteristics, with 95% release over 24 h, compared to conventional liposomes, which released 70% of the drug. Blood compatibility assessments revealed the safety of both formulations for intravenous administration. Cytotoxicity studies conducted on A549 cell lines demonstrated the cytocompatibility of both liposomal types across a range of concentrations, with IC50 values surpassing those of the reference drug, docetaxel. Conclusions: This study underscores the potential of liposomal carriers as effective vehicles for delivering BBG-250, highlighting their stability, biocompatibility, and controlled drug release properties. Despite being slightly less potent than the reference drug, docetaxel, these liposomal formulations hold promise for advancing anticancer strategies. The findings contribute to the evolving landscape of innovative cancer therapy drug delivery systems, offering a novel approach to improving treatment outcomes for cancer patients. The successful development and evaluation of these liposomal carriers pave the way for further investigations and potential clinical applications in the field of cancer therapeutics.Keywords
Funding Information
- AICTE (1-9337642094)
This publication has 29 references indexed in Scilit:
- I-TASSER server: new development for protein structure and function predictionsNucleic Acids Research, 2015
- Engineered Nanoparticles for Drug Delivery in Cancer TherapyAngewandte Chemie International Edition, 2014
- Development and Characterization of Liposomal Doxorubicin Hydrochloride with Palm OilBioMed Research International, 2014
- Purines, Purinergic Receptors, and CancerCancer Research, 2012
- P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatmentJournal of Cellular and Molecular Medicine, 2012
- Impact of extractables/leachables from filters on stability of protein formulationsJournal of Pharmaceutical Sciences, 2011
- Liposomes: From a Clinically Established Drug Delivery System to a Nanoparticle Platform for Theranostic NanomedicineAccounts of Chemical Research, 2011
- Purinergic signalling and disorders of the central nervous systemNature Reviews Drug Discovery, 2008
- Statistical potential for assessment and prediction of protein structuresProtein Science, 2006
- The SWISS-MODEL workspace: a web-based environment for protein structure homology modellingBioinformatics, 2005